Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab with microwave ablation and chemotherapy for metastatic colorectal cancer
ChiCTR2100048492Phase 2Not yet recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Jul 2021
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab in colorectal cancer (CRC), sponsored by Harbin Medical University Cancer Hospital. Primary endpoint: 12-month progression-free survival rate. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
camrelizumab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on ChiCTR2100048492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100048492.